Meeting News Coverage

Similar efficacy found between tedizolid, linezolid

DENVER — A 6-day course of once-daily tedizolid had similar efficacy compared with linezolid every 12 hours for 10 days for the treatment of patients with acute bacterial skin and skin structure infections, according to findings presented at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy.

The two randomized, double-blind phase 3 studies compared 1,333 patients with acute bacterial skin and skin structure infections (ABSSSIs) treated with either 200 mg of tedizolid (TR-701, Trius Therapeutics) once daily or 600 mg of linezolid (Zyvox, Pfizer) every 12 hours for 10 days. Nearly 65%of the patients were male, and the average age was 44 years.

Researchers found that cellulitis was the most common ABSSSIs (tedizolid, 45.3%; linezolid, 45.9%), followed by major cutaneous abscess (tedizolid, 25.3%; linezolid, 24.8%) and wound infections (tedizolid, 29.4%; linezolid, 29.3%).

Treatment-emergent adverse events were similar among both groups (tedizolid, 42.8%; linezolid, 43.2%). However, gastrointestinal treatment-related adverse events were lower in the tedizolid group (16%) compared with the linezolid group (23%). Treatment-related adverse events severe enough to cease treatment were very low (tedizolid, 0.5%; linezolid, 0.9%), as were serious adverse events (tedizolid, 1.8%; linezolid, 2%).

“Overall [treatment-emergent adverse event] rates we similar between [tedizolid] and [linezolid] subjects, though fewer digestive events were observe among [tedizolid] subjects,” researchers wrote. “Fewer patients with abnormally low platelet counts were observe with [tedizolid] than with [linezolid].”

For more information:

De Anda C. Abstract #L-203. Presented at: ICAAC 2013; Sept. 9-13, 2013; Denver.

Disclosure: De Anda reports no relevant financial disclosures.

DENVER — A 6-day course of once-daily tedizolid had similar efficacy compared with linezolid every 12 hours for 10 days for the treatment of patients with acute bacterial skin and skin structure infections, according to findings presented at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy.

The two randomized, double-blind phase 3 studies compared 1,333 patients with acute bacterial skin and skin structure infections (ABSSSIs) treated with either 200 mg of tedizolid (TR-701, Trius Therapeutics) once daily or 600 mg of linezolid (Zyvox, Pfizer) every 12 hours for 10 days. Nearly 65%of the patients were male, and the average age was 44 years.

Researchers found that cellulitis was the most common ABSSSIs (tedizolid, 45.3%; linezolid, 45.9%), followed by major cutaneous abscess (tedizolid, 25.3%; linezolid, 24.8%) and wound infections (tedizolid, 29.4%; linezolid, 29.3%).

Treatment-emergent adverse events were similar among both groups (tedizolid, 42.8%; linezolid, 43.2%). However, gastrointestinal treatment-related adverse events were lower in the tedizolid group (16%) compared with the linezolid group (23%). Treatment-related adverse events severe enough to cease treatment were very low (tedizolid, 0.5%; linezolid, 0.9%), as were serious adverse events (tedizolid, 1.8%; linezolid, 2%).

“Overall [treatment-emergent adverse event] rates we similar between [tedizolid] and [linezolid] subjects, though fewer digestive events were observe among [tedizolid] subjects,” researchers wrote. “Fewer patients with abnormally low platelet counts were observe with [tedizolid] than with [linezolid].”

For more information:

De Anda C. Abstract #L-203. Presented at: ICAAC 2013; Sept. 9-13, 2013; Denver.

Disclosure: De Anda reports no relevant financial disclosures.

    See more from Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)